|
Mar 6
|
Q4 2023 AxoGen Inc Earnings Call
|
|
Mar 5
|
Axogen Inc (AXGN) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full-Year 2023
|
|
Mar 5
|
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
|
|
Mar 5
|
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
|
|
Mar 4
|
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 6
|
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
|
|
Jan 15
|
AxoGen (NASDAQ:AXGN) shareholders have endured a 58% loss from investing in the stock three years ago
|
|
Jan 12
|
Zacks.com featured highlights include Aspen Aerogels, AxoGen and Credo Technology Group
|
|
Jan 4
|
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
|
|
Jan 4
|
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
|
|
Jan 4
|
Axogen Announces Promotions on Research and Development Team
|
|
Dec 26
|
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
|
|
Dec 6
|
Axogen Announces Transition of Finance Team Leadership
|
|
Dec 1
|
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 20
|
Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference
|
|
Nov 17
|
Great week for AxoGen, Inc. (NASDAQ:AXGN) institutional investors after losing 51% over the previous year
|
|
Aug 8
|
The past five years for AxoGen (NASDAQ:AXGN) investors has not been profitable
|
|
Aug 8
|
Q2 2023 AxoGen Inc Earnings Call
|
|
Aug 7
|
AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates
|
|
Aug 7
|
Axogen, Inc. Reports 2023 Second Quarter Financial Results
|